Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NWS0
UPID:
PIHD1_HUMAN
Alternative names:
Nucleolar protein 17 homolog
Alternative UPACC:
Q9NWS0; B4DGN7; B4E2X7; Q9BVL0
Background:
PIH1 domain-containing protein 1, also known as Nucleolar protein 17 homolog, plays a crucial role in cellular processes. It is involved in the assembly of C/D box small nucleolar ribonucleoprotein (snoRNP) particles, enhancing pre-rRNA transcription by recruiting the SWI/SNF complex to rRNA gene promoters. Additionally, it mediates the interaction of TELO2 with the R2TP complex, essential for the stability of key signaling proteins MTOR and SMG1, and positively regulates the mTORC1 complex assembly and activity.
Therapeutic significance:
Understanding the role of PIH1 domain-containing protein 1 could open doors to potential therapeutic strategies.